Stifel Financial
TVTX icon

Stifel Financial’s Travere Therapeutics TVTX Stock Holding History

Stifel Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$313K Sell
10,525
-2,235
-18% -$66.8K ﹤0.01% 3154
2025
Q4 		$488K Buy
+12,760
New +$415K ﹤0.01% 2873

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stifel Financial's TVTX Position: Q1 2026 in Review

Stifel Financial reduced its Travere Therapeutics (TVTX) stake by 18% in Q1 2026, selling an estimated $66.8K and leaving 10,525 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Stifel Financial first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $488K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Stifel Financial held 10,525 shares of Travere Therapeutics worth $313K as of Q1 2026.
  • Stifel Financial sold 2,235 Travere Therapeutics shares in Q1 2026, an estimated $66.8K.
  • Travere Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #3154 holding.
  • Stifel Financial first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Stifel Financial's Travere Therapeutics position peaked at $488K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.